首页> 外文期刊>Endocrine Reviews >Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
【24h】

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies

机译:Minireview:类基础乳腺癌:从分子谱到靶向治疗

获取原文
           

摘要

The classification of breast cancer into molecular subtypes with distinctive gene expression signatures that predict treatment response and prognosis has ushered in a new era of personalized medicine for this remarkably heterogeneous and deadly disease. Basal-like breast cancer (BLBC) is a particularly aggressive molecular subtype defined by a robust cluster of genes expressed by epithelial cells in the basal or outer layer of the adult mammary gland. BLBC is a major clinical challenge because these tumors are prevalent in young woman, often relapsing rapidly. Additionally, most (but not all) basal-like tumors lack expression of steroid hormone receptors (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2, limiting targeted therapeutic options for these predominantly triple-negative breast cancers. This minireview will focus on new insights into the molecular etiology of these poor-prognosis tumors that underlie their intrinsic genomic instability, deregulated cell proliferation and apoptosis, and invasive tumor biology. We will also review ongoing efforts to translate these fundamental insights into improved therapies for women with BLBC.
机译:将乳腺癌分为具有预测治疗反应和预后的独特基因表达特征的分子亚型,已经为这种明显异质性和致命性疾病开启了个性化医学的新时代。基底样乳腺癌(BLBC)是一种特别具有侵略性的分子亚型,由成年乳腺基底层或外层上皮细胞表达的强大基因簇定义。 BLBC是一项重大的临床挑战,因为这些肿瘤在年轻女性中普遍存在,通常会迅速复发。此外,大多数(但不是全部)基底样肿瘤缺乏类固醇激素受体(雌激素受体和孕激素受体)和人表皮生长因子受体2的表达,从而限制了这些三阴性乳腺癌的靶向治疗选择。这份小型回顾将着重于对这些预后不良的肿瘤的分子病因学的新见解,这些分子病因是其固有的基因组不稳定性,失调的细胞增殖和凋亡以及侵袭性肿瘤生物学的基础。我们还将回顾正在进行的努力,以将这些基本见解转化为针对BLBC妇女的改良疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号